"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 17 | 17 |
| 2004 | 0 | 60 | 60 |
| 2005 | 0 | 63 | 63 |
| 2006 | 1 | 56 | 57 |
| 2007 | 0 | 69 | 69 |
| 2008 | 1 | 79 | 80 |
| 2009 | 2 | 107 | 109 |
| 2010 | 0 | 86 | 86 |
| 2011 | 1 | 117 | 118 |
| 2012 | 2 | 87 | 89 |
| 2013 | 2 | 114 | 116 |
| 2014 | 0 | 127 | 127 |
| 2015 | 0 | 137 | 137 |
| 2016 | 0 | 148 | 148 |
| 2017 | 0 | 118 | 118 |
| 2018 | 0 | 130 | 130 |
| 2019 | 1 | 122 | 123 |
| 2020 | 0 | 118 | 118 |
| 2021 | 0 | 112 | 112 |
| 2022 | 0 | 41 | 41 |
| 2023 | 0 | 51 | 51 |
| 2024 | 0 | 85 | 85 |
| 2025 | 0 | 103 | 103 |
| 2026 | 0 | 15 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. Cancer Res. 2026 Apr 02; 86(7):1707-1723.
-
MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models. BMC Cancer. 2026 Feb 14; 26(1).
-
Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis. Nat Commun. 2026 Feb 06; 17(1):1352.
-
Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth. Mol Cancer Ther. 2026 Feb 04; 25(2):257-271.
-
Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor. Nat Commun. 2026 Feb 04; 17(1):1349.
-
Ether lipids influence cancer cell fate by modulating iron uptake. Nat Commun. 2026 Jan 27; 17(1):1835.
-
Evaluating the Antiproliferative Effects of Tri(2-Furyl)- and Triphenylphosphine-Gold(I) Pyridyl- and Pyrimidine-Thiolate Complexes. Biomolecules. 2026 01 15; 16(1).
-
EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge. Nat Commun. 2026 Jan 14; 17(1):1726.
-
FACS-based genome-wide CRISPR screening platform identifies modulators of CD47. Front Immunol. 2025; 16:1684539.
-
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Mol Ther. 2026 Apr 01; 34(4):2154-2174.